Bluebird’s Share Price Skyrocketing On Beta Thalassemia Optimism
This article was originally published in The Pink Sheet Daily
On the strength of interim Phase I/II data presented at ASH and an investor presentation Dec. 10, bluebird bio is enjoying substantial growth in its stock price for the week.
You may also be interested in...
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
bluebird bio LLC has taken in $65 million in venture capital over the past year, thanks to encouraging studies with two different kinds of lentiviral vectors that transfer new copies of genes into patients' own stem cells. Given that vectors have different properties - one integrates into the DNA coding region, the other does not - the company might eventually be able to mix and match therapeutic gene "fillings" to vectors as needed. The start-up is ready to start commercializing gene therapies for serious genetic disorders, starting with ALD and beta-thalassemia. .
Cosmetics companies that disclose the presence of PFAS in their products and explain measures they are taking to minimize PFAS’ presence are better protected from lawsuits, says Dentons US attorney Michael Duvall.